7 Best Peptides for Lean Muscle Mass

What to Know Before Choosing a Peptide for Lean Muscle Mass

The peptide landscape for lean muscle is wider than most guides let on. A compound earns a spot in this list because people use it for this goal or are actively discussing using it, not because it cleared a particular evidence bar or because it carries FDA approval. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible, and evidence strength is stated honestly inside each entry rather than used as a filter at the door. That means some entries here rest on published human trials while others rest entirely on community-reported use. Both belong, and the difference is always named plainly.

The compounds are numbered by how prominently each appears in published research and real-world use for lean muscle mass, not as a recommendation of one compound over another. The number one slot reflects breadth of study and volume of community discussion, not a judgment that compound one is right for you. The right choice depends on your health profile, your training baseline, and the specific kind of muscle support you are after. That personalized decision is exactly what the MyPeptidePal app is built to help you make.

A note on the honest state of the field: as of 2026, no peptide has demonstrated significant lean mass gains in large-scale randomized controlled trials in healthy, actively training adults. Most human studies were conducted in older adults, people with growth hormone deficiency, or disease-specific populations. That gap between community use and clinical proof is real, and it is named for each compound. Knowing the gap does not make these compounds unworthy of consideration. It makes you a better-informed researcher.

1. CJC-1295: The Foundation of Most Lean Muscle Stacks

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, the hypothalamic signal that tells the pituitary gland to secrete growth hormone. The key word in that sentence is "tells": CJC-1295 works upstream, prompting your own pituitary to release GH in pulses rather than introducing exogenous hormone. That distinction matters because pulsatile release, growth hormone coming out in bursts that mirror the body's natural rhythm, is associated with better anabolic signaling and less receptor desensitization than continuous flat-line elevation.

The version most commonly used for lean muscle goals is CJC-1295 without DAC, also called Mod GRF 1-29. The DAC variant has a half-life measured in days and blunts the pulsatile pattern. The without-DAC form has a short active window of roughly 30 minutes, which means it amplifies a natural GH pulse rather than overriding it. Once GH is released, the liver converts it into IGF-1, the signal that actually reaches muscle cells and activates the protein synthesis machinery inside them.

Small randomized controlled trials have shown lean mass increases in the range of one to two kilograms over eight to sixteen weeks in older adults with low baseline GH. The populations were sarcopenic adults and people with growth hormone insufficiency, not trained athletes. No large Phase III trial has been run in healthy exercising adults, and the frequently cited combination of CJC-1295 with Ipamorelin has zero published peer-reviewed human studies testing it as a combined protocol. Community use is extremely widespread, and the compound consistently appears as the base layer of muscle-focused peptide stacks. Most practitioners who prescribe GH secretagogues off-label start here.

CJC-1295 was included in the FDA's compounding ban of 2023 to 2024, which means it is not currently available through licensed compounding pharmacies in the United States. Sourcing outside that channel places it in research-chemical territory, with all the quality and purity uncertainties that category carries.

2. Ipamorelin: The Selective Growth Hormone Pulse

Ipamorelin is a synthetic growth hormone-releasing peptide and ghrelin receptor agonist, which puts it in a different receptor class than CJC-1295. Where CJC-1295 binds GHRH receptors, Ipamorelin binds GHS-R1a, the ghrelin receptor on pituitary cells. Those are two different locks on the same door. When both are activated together, the resulting GH release is substantially greater than either compound produces alone, which is why CJC-1295 and Ipamorelin are almost always discussed as a pair.

What sets Ipamorelin apart from the other compounds in its class is selectivity. At the doses used in research and in community protocols, Ipamorelin does not significantly activate cortisol or prolactin pathways. Cortisol is a catabolic hormone that breaks down muscle tissue, so a GHRP that simultaneously raises cortisol is working against part of the goal. Ipamorelin avoids that trade-off. GHRP-2 raises cortisol by roughly 15 to 20 percent at active doses. Hexarelin produces the largest GH spikes of any GHRP but comes with meaningful desensitization and hormonal interference. Ipamorelin sits in the middle: solid GH stimulation, clean hormonal profile.

Published human evidence follows the same pattern as CJC-1295: small studies in elderly and sarcopenic populations, meaningful signal, no large Phase III data in healthy athletes. The regulatory picture changed in late 2024, when Ipamorelin was removed from the FDA compounding ban that kept CJC-1295 off pharmacy shelves. That makes Ipamorelin currently the most accessible of the injectable GH secretagogues through licensed compounding pharmacies in the United States, a meaningful practical distinction for anyone working with a physician in this space.

3. Tesamorelin: The One With an FDA Approval

Tesamorelin, sold under the brand name Egrifta, is the only peptide in this space that carries an FDA approval with any body-composition dimension to it. The approval is for reducing visceral fat in people with HIV-associated lipodystrophy, a condition involving abnormal fat redistribution. That is a specific medical indication, not a general muscle-building clearance, and the compound is not approved for lean muscle use in healthy adults. That said, it is available by prescription, can be prescribed off-label by a physician, and is used in clinical and functional medicine settings for body recomposition.

The mechanism is the same GHRH-receptor pathway as CJC-1295: Tesamorelin binds GHRH receptors on pituitary cells, stimulates pulsatile GH release, and drives hepatic IGF-1 production. Its molecular structure is distinct enough from CJC-1295 to have cleared the FDA's regulatory process where CJC-1295 did not. Clinical data from the HIV lipodystrophy population shows visceral fat reduction alongside increased GH and IGF-1 levels, and some studies in that group show preserved or modestly increased muscle area. The practical framing for recomposition use is this: Tesamorelin is the compound people reach for when they want to reduce fat and support lean tissue simultaneously, in a single prescription-accessible compound.

The honest framing on evidence for healthy adults is that the controlled trial data comes from a disease-specific population, and there is no large randomized study in healthy, training individuals. For someone who qualifies for a prescription and is working with a physician on body recomposition, it is the one compound in this category with a verifiable supply chain, professional oversight, and a legitimate regulatory track record.

4. Follistatin-344: Targeting the Brake on Muscle Growth

To understand Follistatin-344, you need to understand myostatin. Myostatin is a protein your muscles produce that acts as a biological brake on their own growth. The body uses it to limit how large muscles can become, which makes evolutionary sense as a check against metabolic excess. The problem for anyone trying to build lean muscle is that this brake is always engaged to some degree. Follistatin-344 works by binding circulating myostatin before it can reach the receptors on muscle cells, neutralizing the signal that would otherwise suppress muscle differentiation and new fiber formation.

The molecular sequence runs like this: myostatin binds Activin Type IIB receptors on muscle cells, which fires a signaling cascade through proteins called Smad2 and Smad3, which then travel to the cell nucleus and suppress the genes that drive muscle development. Follistatin-344 intercepts myostatin before that cascade can start. The Smad2/3 pathway never fires, the suppression is never applied, and satellite cells, the stem cells that give rise to new muscle fibers, are free to proliferate and differentiate. The conceptual result is muscle tissue that can develop beyond its normal genetic ceiling.

The evidence requires honest framing. Follistatin-344 has been studied in preclinical research and limited clinical contexts, but there are no large-scale published randomized controlled trials in healthy adult populations as of 2026. What the community uses and reports is real, but the human clinical data to match the mechanism is thin. The compound is sold as a research chemical, it is not FDA-approved for any indication, and it is banned by WADA. It occupies a distinct conceptual lane from the GH secretagogues: where those compounds amplify a hormonal signal, Follistatin-344 removes an inhibitory one. That is why it is discussed as a complement to GH peptides rather than a replacement for them.

5. MK-677: The Oral Option for Sustained GH Elevation

MK-677, also known as Ibutamoren, is technically a small molecule rather than a true peptide, but it is consistently grouped with peptides in this space because its mechanism and use context are identical to the injectable GHRPs. Its real distinction is delivery: MK-677 is the only compound in this entire category available in oral form. For people with needle aversion or practical barriers to injection, that is a meaningful difference.

The mechanism is ghrelin receptor agonism, the same GHS-R1a pathway as Ipamorelin. MK-677 mimics ghrelin's action on pituitary cells, stimulating GH release. What makes it behave differently from injectable GHRPs is its half-life, approximately 24 hours, which is orders of magnitude longer than any peptide in this class. That sustained activity means GH and IGF-1 levels stay elevated throughout the day, including during sleep, when most natural GH release occurs. The practical effect is a sustained anabolic environment rather than discrete GH pulses.

The human evidence for MK-677 is among the strongest in this category. A 12-month randomized controlled trial showed meaningful lean mass increases, and the compound's effects on GH and IGF-1 elevation in humans are well-established across multiple studies. The caution that comes alongside this evidence is real: insulin resistance is a documented risk with extended use, particularly beyond sixteen weeks. Elevated fasting glucose and increased appetite are commonly reported, and the appetite stimulation can work against fat loss goals. The FDA banned compounding of MK-677 in 2023 to 2024 over safety concerns including cardiac events, and that ban remained in effect as of the most recent available information. Outside that channel, the compound is sold as a research chemical. It is banned by WADA.

6. IGF-1 LR3: Direct Anabolic Signaling and New Fiber Formation

IGF-1 LR3 occupies a unique position in this field because it operates downstream of the entire growth hormone axis. Where CJC-1295, Ipamorelin, MK-677, and Tesamorelin all work by stimulating GH release and relying on the liver to produce IGF-1 as a secondary step, IGF-1 LR3 bypasses that upstream process entirely. It delivers the anabolic signal that GH would eventually produce, but directly, without requiring the pituitary or the liver to be in the chain.

The LR3 modification extends the compound's active window from roughly 12 to 15 minutes for endogenous IGF-1 to approximately 20 to 30 hours. That extension comes from reduced binding to IGF-binding proteins, the proteins that sequester IGF-1 in circulation and limit how long it stays active. The result is sustained engagement with IGF-1 receptors on muscle cells across an extended window. At the receptor, IGF-1 LR3 activates the PI3K/Akt/mTORC1 pathway: a signaling cascade that increases the rate of muscle protein synthesis, reduces muscle protein breakdown, and activates satellite cells. Satellite cells are the stem cells of skeletal muscle, and their activation is the mechanism behind potential hyperplasia, the formation of new muscle fibers rather than just enlargement of existing ones. Most muscle-building interventions primarily produce hypertrophy. IGF-1 LR3 is the compound most consistently cited in the community for potential hyperplastic effects.

The evidence gap is significant and must be stated plainly. No published human clinical trials have focused on IGF-1 LR3 for muscle growth efficacy as of 2026. The mechanistic picture comes from preclinical research in animal models and cell culture experiments. What exists in the human context is entirely user-reported experience from community protocols, where the compound has a consistent reputation as the most potent single option for new muscle fiber development. The compound is not FDA-approved, is sold as a research chemical, and is banned by WADA. Because it operates on the same downstream pathway as insulin, hypoglycemia is a real risk associated with its use in community reports.

7. BPC-157: Keeping the Training That Builds Muscle Intact

BPC-157 does not build lean muscle directly. It earns its place on this list for a different reason: it consistently appears in the community discussion around muscle-building peptide use, and the mechanism behind that presence is straightforward to explain. BPC-157 is a synthetic pentadecapeptide, built from 15 amino acids, derived from a protective compound found in gastric secretions. Its studied effects center on tissue repair, specifically tendons, ligaments, and muscle injuries, alongside anti-inflammatory activity and angiogenesis, the formation of new blood vessels that improves nutrient delivery to healing tissue.

The indirect path to lean muscle is this: consistent, progressive resistance training is the actual driver of muscle growth. Peptides in this category accelerate the hormonal environment that training works in. But training also creates injuries, and injuries interrupt training. BPC-157 users most commonly report faster resolution of soft tissue injuries, reduced joint pain, and what many describe as fortified connective tissue over time. If the compound does what community reporting suggests, the benefit for lean muscle is measured in training sessions that do not get missed.

The evidence base is the thinnest on this list. No randomized controlled trial data exists for BPC-157 in humans for any muscle-building application as of 2026. The only human data available is a small retrospective case series of 12 patients with no control group and no blinding. The preclinical evidence in animal models is more substantial, particularly for tendon healing and angiogenesis, but the animal-to-human translation has not been formally established. What exists for the muscle-building context is user-reported experience from community protocols. That experience is widespread and consistent across many independent sources, and it is plausible given the mechanism. The evidence is experiential rather than clinical, and that is the accurate description of where this compound stands.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides legal to buy in the United States?

The legal picture varies by compound and is not static. Tesamorelin is FDA-approved and available by prescription, though only for its approved indication. Ipamorelin is currently accessible through licensed compounding pharmacies in the US following its removal from the FDA compounding ban in late 2024. CJC-1295 and MK-677 remain on the FDA compounding ban list as of the most recent available information, which means they are sourced only through research-chemical channels. Follistatin-344 and IGF-1 LR3 are sold as research chemicals with no approved human-use indication. BPC-157's regulatory status has shifted over time, and confirming current standing with a qualified healthcare professional is the reliable approach.

How long does it take for these compounds to show results?

The honest answer is that it varies significantly by compound and by individual. Community-reported experience with GH secretagogues like CJC-1295 and Ipamorelin typically describes a gradual onset, with improved sleep quality and recovery noticeable in the first few weeks and meaningful body composition changes appearing over eight to sixteen weeks of consistent use alongside training. The small human studies in older adults showed measurable lean mass gains over twelve to sixteen weeks. IGF-1 LR3 users in community protocols often report faster subjective changes, but with no controlled human timeline data available, that framing remains experiential rather than clinically established.

Do these peptides work without resistance training?

They work with training and add very little without it. The honest framing from community experience and from the limited human data is that GH secretagogues and IGF-1 compounds amplify an anabolic environment, but that environment needs the stimulus of resistance training to produce lean mass. A growth signal without a training signal tends to produce minimal muscle and may instead contribute to water retention or fat storage. The compounds on this list are best understood as accelerants for a process that training initiates, not replacements for it.

What are the main safety considerations for these compounds?

Safety profiles differ meaningfully by compound. Ipamorelin has a relatively clean profile at studied doses, without the cortisol and prolactin effects seen with other GHRPs. MK-677 carries a real insulin resistance risk with extended use beyond sixteen weeks, and the FDA compounding ban reflects broader cardiac and metabolic safety concerns. IGF-1 LR3 carries hypoglycemia risk because it operates on the same downstream pathway as insulin. Follistatin-344 removes a biological regulator that exists for a reason, and the long-term implications of sustained myostatin inhibition in healthy adults have not been established by human research. For any of these compounds, working with a qualified medical professional substantially changes the risk picture.

Can these peptides be used together?

Combining peptides is common in practice, and the CJC-1295 plus Ipamorelin pairing is the most frequently cited combination for lean muscle goals. The rationale is mechanistic: the two compounds bind different receptor systems, so their effects are complementary rather than redundant. That said, there are zero published peer-reviewed human studies specifically evaluating the CJC-1295 plus Ipamorelin combination as a protocol, so the evidence for the stack itself is extrapolated from individual compound data and community reporting. Adding multiple compounds increases both the potential anabolic effect and the complexity of managing side effects and interactions. Personalized stacking decisions are exactly the kind of judgment the MyPeptidePal app is built to support.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for lean muscle mass in one place.